- NORTH AMERICA EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Resolve Therapeutics Announces Publication Of Clinical Data Demonstrating The Role Of Circulating RNA In Systemic Lupus Erythematosus
Resolve Therapeutics is a privately held biotechnology company that is dedicated to improving the lives of patients with lupus and Sjögren’s syndrome through the development of its platform of targeted nuclease therapeutics. In addition to the lead molecule, RSLV-132, the company is developing additional molecules that contain both RNase and DNase activities, which may also …
Resolve Therapeutics is a privately held biotechnology company that is dedicated to improving the lives of patients with lupus and Sjögren’s syndrome through the development of its platform of targeted nuclease therapeutics. In addition to the lead molecule, RSLV-132, the company is developing additional molecules that contain both RNase and DNase activities, which may also be useful in the treatment of lupus, Sjogrens syndrome and other autoimmune diseases. Resolve is funded by a syndicate of venture capital firms including, New Science Ventures, WRF Capital, and Easton Capital. For more information on the company please visit: https://www.resolvebio.com.
Contact:
James Posada, Ph.D.
Chief Executive Officer
Resolve Therapeutics, LLC
(208) 727-7010
jp@resolvebio.com
Logo – https://photos.prnewswire.com/prnh/20160210/331815LOGO
To view the original version on PR Newswire, visit:https://www.prnewswire.com/news-releases/resolve-therapeutics-announces-publication-of-clinical-data-demonstrating-the-role-of-circulating-rna-in-systemic-lupus-erythematosus-300316369.html
SOURCE Resolve Therapeutics, LLC
Related Links
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.